Literature DB >> 27898978

Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints.

Tracy Rupp1, Diana Zuckerman1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 27898978     DOI： 10.1001/jamainternmed.2016.7761

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  18 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  The Cancer Drugs Fund in Practice and Under the New Framework.

Authors:  Celia Sabry-Grant; Kinga Malottki; Alexander Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

3.  Can the FDA Help Reduce Drug Prices or the Cost of Medical Care?

Authors:  Diana M Zuckerman
Journal:  Am J Public Health       Date:  2017-11       Impact factor: 9.308

4.  A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors:  Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal:  Int J Health Serv       Date:  2022-05-12       Impact factor: 1.851

5.  Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.

Authors:  Jacob J Mandel; Shlomit Yust-Katz; Akash J Patel; David Cachia; Diane Liu; Minjeong Park; Ying Yuan; Thomas A Kent; John F de Groot
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

6.  Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation.

Authors:  Kurinchi S Gurusamy; David Moher; Marilena Loizidou; Irfan Ahmed; Marc T Avey; Carly C Barron; Brian Davidson; Miriam Dwek; Christian Gluud; Gavin Jell; Kiran Katakam; Joshua Montroy; Timothy D McHugh; Nicola J Osborne; Merel Ritskes-Hoitinga; Kees van Laarhoven; Jan Vollert; Manoj Lalu
Journal:  PeerJ       Date:  2021-01-27       Impact factor: 2.984

Review 7.  Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.

Authors:  Kurinchi Selvan Gurusamy; Lawrence Mj Best; Cynthia Tanguay; Elaine Lennan; Mika Korva; Jean-François Bussières
Journal:  Cochrane Database Syst Rev       Date:  2018-03-27

8.  Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.

Authors:  Eric Van Cutsem; Alfredo Falcone; Rocio Garcia-Carbonero; Yoshito Komatsu; Alessandro Pastorino; Marc Peeters; Yasuhiro Shimada; Kentaro Yamazaki; Takayuki Yoshino; Alberto Zaniboni; Nadia Amellal; Akira Kanehisa; Robert Winkler; Lukas Makris; Robert J Mayer; Atsushi Ohtsu; Josep Tabernero
Journal:  ESMO Open       Date:  2017-11-23

9.  Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Authors:  Robert Kemp; Vinay Prasad
Journal:  BMC Med       Date:  2017-07-21       Impact factor: 8.775

10.  Why clinical trial outcomes fail to translate into benefits for patients.

Authors:  Carl Heneghan; Ben Goldacre; Kamal R Mahtani
Journal:  Trials       Date:  2017-03-14       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.